



Search Web

HOME

INVESTING

NEWS

VIDEO

MY PORTFOLIOS

PERSONAL FINANCE

MARKETS ECONOMY SINGAPORE TECHNOLOGY PROPERTY BLOGS PHOTOS VIDEO

Enter Symbol

Get Quotes

Wed, Jan 13, 2016, 7:05 PM SGT - Singapore Markets closed

MedGenome to Present on OncoPept - a Point Solution in Cancer Immunotherapy at the Novel Immunotherapeutics Summit 2016



Press Release: MedGenome Labs Pvt. Ltd. - 23 hours ago

Share Tweet LinkedIn Share +1 Print

SAN FRANCISCO, January 12, 2016 /PRNewswire/ --

Our Analysis Reveals That Tongue and Buccal Cancers Harbor a set of Dual-purpose Tumor Neo-antigens That can be Used as Cancer Vaccines in a Therapeutic Setting, and as Biomarkers of Response to Select Patients for Cancer Immunotherapy

MedGenome will present results from their Head & Neck cancer study in which published genomics data from over 400 Head & Neck cancer samples have been analyzed to identify potential vaccine candidates using MedGenome's proprietary OncoPept platform at the **Novel Immunotherapeutics Summit 2016, on January 25-26, 2016 at San Diego, CA.**

(Logo: <http://photos.prnewswire.com/prnh/20160112/784044>)

The analysis shows that differential gene expression between tongue and buccal cancers produce both unique and shared vaccine candidates that can be used in combination therapies. Several studies have shown that the efficacy and durability of response to the checkpoint control inhibitors, which complement the traditional approach of targeting driver genes in cancer, are significantly enhanced by combining vaccine candidates derived from neo-antigens expressed by the tumor cells.


MedGenome's OncoPept is an integrated platform that uses exome sequencing, RNA sequencing and computational methods to characterize tumor neo-antigens, analyze T-cell neo-epitopes and reveal gene expression signatures. The platform has various pre-clinical and clinical research applications.

About MedGenome:

MedGenome is a genomics-driven research and diagnostics company with a mission to improve global health by decoding the genetic information contained in an individual's genome. Our powerful genomics solutions accelerate drug discovery research for pharma and biotech companies. Our unique access to genomics data with clinical and phenotypic data provides insights into complex diseases at the genetic and molecular level to facilitate research in personalized healthcare. MedGenome is the market leader for genetic diagnostic testing in India and has worked with thousands of doctors, hospitals, and patients across India by applying Next Generation Sequencing (NGS) techniques to large disease cohorts in cancer, eye and neurological disorders, diabetes, cardiovascular diseases and rare cancers.

For more information, visit us at <http://www.medgenome.com>

LATEST VIDEOS



Petrodollars Becoming Petro



China's Choice: Devalued Yuan or



Should Oil Companies Cut Their Dividend?



Sovereign Risk: Why Commodities Are the

Other videos »

TOP STORIES

- 1 person detained in connection with Istanbul suicide attack Associated Press
- 10 Things to Know for Today Associated Press
- Chinese exports down in December, but better than forecast AFP News
- The Latest: Pope prays for Istanbul suicide blast victims Associated Press
- Retired Thai general to head rubber body amid price crisis Associated Press

More »

Recent Quotes

Portfolios

| Symbol | Price | Change | % Chg |
|--------|-------|--------|-------|
|--------|-------|--------|-------|

Your most recently viewed tickers will automatically show up here if you type a ticker in the "Enter symbol/company" at the bottom of this module.

Enter Symbol

Get Quotes

SINGAPORE »

- Offshore Yuan Set for Record Five-Day Gain as China Curbs Supply